Oral tacrolimus as maintenance therapy for refractory ulcerative colitis-an analysis of outcomes in two London tertiary centres

Journal of Crohn's and Colitis

Volumn 7, Issue 11, 2013, Pages

  Landy, Jonathan ^a   Wahed, Mahmood ^b   Peake, Simon T C ^a   Hussein, Mohammed ^a   Ng, Siew C ^c   Lindsay, James O ^b   Hart, Ailsa L ^a  

^a ST MARK S HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Inflammatory bowel disease; Tacrolimus; Ulcerative colitis

Indexed keywords

CYCLOSPORIN A; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; COLON RESECTION; COLONOSCOPY; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; KIDNEY DYSFUNCTION; LEUKAPHERESIS; LEUKOPENIA; LONG TERM CARE; MAINTENANCE THERAPY; MALE; OPERATION DURATION; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PANCOLITIS; PARESTHESIA; PRIORITY JOURNAL; PROCTITIS; REMISSION; RETROSPECTIVE STUDY; SCORING SYSTEM; SEPSIS; STEROID THERAPY; TERTIARY HEALTH CARE; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; ULCERATIVE COLITIS; UNITED KINGDOM;

INFLAMMATORY BOWEL DISEASE; TACROLIMUS; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; COLECTOMY; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; LONDON; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TERTIARY CARE CENTERS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84884817246     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.03.008     Document Type: Article

References (26)

1. Cottone M., Scimeca D., Mocciaro F., Civitavecchia G., Perricone G., Orlando A. Clinical course of ulcerative colitis. Dig Liver Dis Jul 2008, 40(Suppl. 2):S247-S252.
2. Fraser A.G., Orchard T.R., Jewell D.P. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30year review. Gut Apr 2002, 50(4):485-489.
3. Sandborn W., Sutherland L., Pearson D., May G., Modigliani R., Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000, 2:CD000545.
4. Mowat C., Cole A., Windsor A., Ahmad T., Arnott I., Driscoll R., et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011, 60(5):571-607.
5. Fraser A.G., Morton D., McGovern D., Travis S., Jewell D.P. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther Apr 2002, 16(4):693-697.
6. Wahed M., Louis-Auguste J.R., Baxter L.M., Limdi J.K., McCartney S.A., Lindsay J.O., et al. Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine/mercaptopurine. Aliment Pharmacol Ther Sep 15 2009, 30(6):614-620.
7. Oren R., Arber N., Odes S., Moshkowitz M., Keter D., Pomeranz I., et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology May 1996, 110(5):1416-1421.
8. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med Dec 8 2005, 353(23):2462-2476.
9. Sandborn W.J., van Assche G., Reinisch W., Colombel J.F., D'Haens G., Wolf D.C., et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology Feb 2012, 142(2):257-265. [e1-3].
10. Sandborn W.J., Rutgeerts P., Feagan B.G., Reinisch W., Olson A., Johanns J., et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology Oct 2009, 137(4):1250-1260. [quiz 520].
11. Thomson A.W., Bonham C.A., Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit Dec 1995, 17(6):584-591.
12. Fellermann K., Ludwig D., Stahl M., David-Walek T., Stange E.F. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol Oct 1998, 93(10):1860-1866.
13. Baumgart D.C., Wiedenmann B., Dignass A.U. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther May 15 2003, 17(10):1273-1281.
14. Hogenauer C., Wenzl H.H., Hinterleitner T.A., Petritsch W. Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther Aug 15 2003, 18(4):415-423.
15. Ogata H., Matsui T., Nakamura M., Iida M., Takazoe M., Suzuki Y., et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut Sep. 2006, 55(9):1255-1262.
16. Ogata H., Kato J., Hirai F., Hida N., Matsui T., Matsumoto T., et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis May 2012, 18(5):803-808.
17. Baumgart D.C., Pintoffl J.P., Sturm A., Wiedenmann B., Dignass A.U. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease-a long-term follow-up. Am J Gastroenterol May 2006, 101(5):1048-1056.
18. Benson A., Barrett T., Sparberg M., Buchman A.L. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflamm Bowel Dis 2008, 14(1):7-12.
19. Yamamoto S., Nakase H., Mikami S., Inoue S., Yoshino T., Takeda Y., et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther 2008, 28(5):589-597.
20. Yamamoto S., Nakase H., Matsuura M., Masuda S., Inui K., Chiba T. Tacrolimus therapy as an alternative to thiopurines for maintaining remission in patients with refractory ulcerative colitis. J Clin Gastroenterol Jul. 2011, 45(6):526-530.
21. Ng S.C., Arebi N., Kamm M.A. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm Bowel Dis 2007, 13(2):129-134.
22. Lichtiger S., Present D.H., Kornbluth A., Gelernt I., Bauer J., Galler G., et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med Jun. 30 1994, 330(26):1841-1845.
23. Herrlinger K.R., Koc H., Winter S., Teml A., Stange E.F., Fellermann K., et al. ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis. Clin Pharmacol Ther Mar 2011, 89(3):422-428.
24. Ardizzone S., Cassinotti A., Duca P., Mazzali C., Penati C., Manes G., et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol Jun 2011, 6:483-489. [e3].
25. Kobayashi T., Naganuma M., Okamoto S., Hisamatsu T., Inoue N., Ichikawa H., et al. Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitis. J Gastroenterol Nov 2010, 45(11):1129-1137.
26. Colombel J.F., Rutgeerts P., Reinisch W., Esser D., Wang Y., Lang Y., et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology Oct 2011, 141(4):1194-1201.